The effects of a new adrenergic blocking agent (K4423) on exercise tolerance in angina pectoris.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009284:Naphthols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005082:Physical Exertion / Q000187:drug effects*; D010919:Placebos; D011412:Propanolamines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D009284:Naphthols; D010919:Placebos; D011412:Propanolamines